{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-055500","form_type":"8-K","ticker":"BCAX","cik":"0002023658","company_name":"Bicara Therapeutics Inc.","filed_at":"2026-08-11T11:36:11+00:00","discovered_at":"2026-08-11T11:40:00.297379+00:00","generated_at":"2026-08-11T11:40:11.599885+00:00","sec_items":["2.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Bicara names Ryan Cohlhepp CEO effective Jan 2027; Q2 net loss widens to $55.4M","bullets":["Net loss $55.4M in Q2 2026 vs $27.4M in Q2 2025; R&D expense $45.8M (up from $24.8M).","Cash, equivalents, marketable securities $497.3M at June 30, 2026; funded into 1H 2029.","Ryan Cohlhepp (President/COO) to become CEO Jan 1, 2027; Claire Mazumdar moves to Vice Chair.","Tanya Green promoted to COO, Jenn Larson appointed CFO effective Aug 12, 2026; other C-suite changes.","FORTIFI-HN01 pivotal trial substantially enrolled by year-end; interim topline mid-2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-055500","json":"https://secwatch.observer/filing/0001628280-26-055500.json","markdown":"https://secwatch.observer/filing/0001628280-26-055500.md","text":"https://secwatch.observer/filing/0001628280-26-055500.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2023658/000162828026055500/0001628280-26-055500-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2023658/000162828026055500/bcax-20260811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-11T11:40:11.599885+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}